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Background: Upon lipopolysaccharide (LPS) stimulation, activation of both the Toll-like receptor 4 (TLR4) and
phosphoinositide 3-kinase (PI3K) pathways serves to balance proinflammatory and anti-inflammatory responses.
Although the antagonist to TLR4 represents an emerging promising target for the treatment of sepsis; however,
the role of the PI3K pathway under TLR4-null conditions is not well understood. This goal of this study was to
investigate the effect of inhibition of PI3K on innate resistance to LPS toxicity in a murine model.
Results: The overall survival of the cohorts receiving intraperitoneal injections of 100, 500, or 1000 μg LPS from
Escherichia coli serotype 026:B6 after 7 d was 100%, 10%, and 10%, respectively. In contrast, no mortality was noted
after 500-μg LPS injection in Tlr4−/− mice. When the PI3K inhibitor LY294002 was injected (1 mg/25 g body weight)
1 h prior to the administration of LPS, the overall survival of the Tlr4−/− mice was 30%. In the Tlr4−/− mice, the LPS
injection induced no NF-κB activation but an increased Akt phosphorylation in the lung and liver, when compared
to that of the C57BL/6 mice. Injection of 500 μg LPS led to a significant induction in O2− detected by electron
paramagnetic resonance (EPR) spin trapping spectroscopy in the lung and liver at 3 and 6 h in C57BL/6 but not
Tlr4−/− mice. Addition of LY294002 only significantly increased the O2
− level in the lung and liver of the Tlr4−/− mice
but not in the C57BL/6 mice following 500-μg LPS injection. In addition, the serum IL-1β and IL-2 levels were more
elevated in C57BL/6 mice than in Tlr4−/− mice. Notably, IL-1β and IL-2 were significantly increased in Tlr4−/− mice
but not in the C57BL/6 mice when the PI3K pathway was inhibited by LY294002 prior to LPS injection.
Conclusions: In this study, we demonstrate that innate resistance to LPS toxicity in Tlr4−/− mice is impaired by
inhibition of the PI3K pathway, with a corresponding increase in mortality and production of tissue O2
− and
inflammatory cytokines.
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Lipopolysaccharide (LPS) from gram-negative bacteria is a
potent Toll-like receptor 4 (TLR4) ligand and an inflam-
matory mediator that activates well characterized pathways
involving nuclear factor-kappa B (NF-κB) signal transduc-
tion and subsequent expression of inflammatory cytokines
[1]. TLRs signal through two main pathways: a myeloid dif-
ferentiation factor (MyD)88-dependent pathway that acts* Correspondence: m93chinghua@gmail.com
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unless otherwise stated.via NF-κB to induce pro-inflammatory cytokines, and a
MyD88-independent pathway that acts via type I inter-
ferons to increase the expression of interferon-inducible
genes [2,3]. TLR4 stimulation also induces concomitant
activation of the phosphoinositide 3-kinase (PI3K) and
the downstream target serine/threonine kinase Akt
[4-9]. The p85 regulatory domain subunit of PI3K has
been reported to associate with TLR4 in cells, and co-
immunoprecipitation experiments demonstrated that
MyD88 binds p85 upon LPS stimulation [10,11]. It has
been demonstrated that, upon LPS stimulation, the
kinetics of MyD88 and PI3K recruitment to TLR4 ared. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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bind as a dimer and have a direct role in the activation
of PI3K [12,13]. The induced concomitant activation of
the PI3K/Akt pathway following TLR4 stimulation was re-
cently shown to negatively regulate the pro-inflammatory
response both in vitro and in vivo [4-9]. LPS-induced
phosphorylation of Akt was reported to be completely
TLR4-dependent [14], and can be suppressed by a specific
PI3K inhibitor, LY294002 [15].
The PI3K/Akt signaling pathway is one of the most
critical pathways involved in regulation of cell survival
[16] and inflammatory responses [17]. The PI3K/Akt sig-
naling pathway may be an endogenous negative feedback
regulator and/or compensatory mechanism that serves
to limit pro-inflammatory and apoptotic events in re-
sponse to injurious stimuli [18-20]. Recent evidence indi-
cates that there is crosstalk between the TLR and PI3K/
Akt signaling pathways [11,12,18-20]. LPS-induced TLR4
stimulation protects monocytes and human dendritic cells
from apoptosis through PI3K/Akt- and NF-κB-dependent
mechanisms by regulating the phosphorylation of NF-κB
p65 at serine 536 and Akt at serine 473 [12]. In addition,
in a murine model of cecal ligation and puncture-induced
polymicrobial sepsis, inhibition of PI3K activity increased
serum cytokine levels and mortality [20]. In contrast to
these findings, stimulation of the PI3K pathway was corre-
lated with improved outcome [20]. Administration of
endotoxin to PI3Kγ-knockout mice resulted in decreased
acute lung injury, suggesting that the PI3K pathway plays
an important role in the pathophysiology of endotoxic
injury [21].
Sepsis mice induced by the administration of LPS were
employed as a redox disruption model because sepsis is
well known to be a systemic inflammatory response syn-
drome related to the generation of reactive oxygen spe-
cies (ROS) [22]. LPS has been shown to generate ROS
through the stimulation of LPS-binding proteins and
Toll-like receptors [23]. Furthermore, the released cyto-
kines were shown to induce ROS generation in endothe-
lial cells [24]. The expression level of TLR4 determines
the degree of LPS susceptibility in mice [25]. Manipula-
tion of TLR4 activation has been hypothesized to modu-
late the innate resistance to LPS toxicity. For example,
C57BL/10ScCr mice carry a deletion of the Tlr4 gene,
and are thus refractory to LPS effects [25,26]. TLR4 an-
tagonism also restores the function of septic organs dur-
ing endotoxemia [27,28]. The simultaneous activation of
both the TLR4 and PI3K pathways upon LPS stimulation
has been reported to balance the pro-inflammatory and
anti-inflammatory response [29]; Although the antagon-
ist to TLR4 represents an emerging promising target for
the treatment of sepsis; however, the role of PI3K path-
way under TLR4-null conditions is not well understood.
In this study, we demonstrate that innate resistance toLPS toxicity in Tlr4−/− mice is reduced by the inhibition
of the PI3K pathway, with a corresponding increase in




Eight to twelve week old male mice weighing 25–30 g
were used in the study. Tlr4−/− (C57BL/10ScNJ) mice
were purchased from Jackson Laboratory (Bar Harbor,
ME, USA). C57BL/6 mice were purchased from the Na-
tional Laboratory Animal Center, Taiwan. The murine
strain C57BL/10ScNJ mice have a deletion of the Tlr4
gene that results in absence of both mRNA and protein
and thus in defective response to LPS stimulation. C57BL/
6 was used as a control. All housing conditions and surgi-
cal procedures, analgesia, and assessments were in accord-
ance with national and institutional guidelines, and an
Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC)–accredited SPF facility was used.
The animal protocols were approved by the Institutional
Animal Care and Use Committee (IACUC) of Kaohsiung
Chang Gung Memorial Hospital.
Survival studies
LPS from Escherichia coli serotype 026:B6 (catalog no.
L3755) was purchased from Sigma-Aldrich (St. Louis,
MO, USA). To profile the LPS toxicity, C57BL/6 mice were
injected intraperitoneally (i.p.) with 100, 500, 1000 μg of
LPS reconstituted in 100 μL of phosphate-buffered saline
(PBS) (n = 10 in each group) for survival studies. The mice
were returned to their cages after LPS injection and closely
monitored for up to 7 d. Mice were given ad libitum access
to food and water at all times. Additional groups of Tlr4−/−
mice received i.p. injections of 500 μg LPS in the presence
or absence of i.p. PI3K inhibitor LY294002 (1 mg/25 g
body weight, Sigma-Aldrich) and were observed for sur-
vival studies (n = 10 in each group). LY294002 was injected
1 h prior to the administration of LPS.
Blood and tissue samples
C57BL/6 and Tlr4−/− mice were injected i.p. with 500 μg
LPS and sacrificed at 3- or 6-h post-injection. The con-
trol group was injected with 100 μL PBS. Additional
groups of Tlr4−/− mice received i.p. injections of (1 mg/
25 g body weight) LY294002 1 h prior to the injection of
500 μg LPS (n = 6 in each group). Whole blood was drawn
from the mice, and tissues, including the lungs, liver, and
spleen, were harvested for western blot analysis of Akt
phosphorylation and nuclear translocation of p65 as well
as the measurement of superoxide (O2
−) production.
Whole blood samples (1 mL per mouse) were collected
into tubes containing an anticoagulant and incubated at
room temperature for 15 min prior to centrifugation at
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slowly removed from the corresponding layers and the
serum was extracted and stored at −80°C before process-
ing for cytokine assays.
Western blot analysis
The harvested lung, liver, and spleen tissues from wild
type C57BL/6 mice and Tlr4−/− mice injected with 500 μg
LPS in the presence or absence of LY294002 were har-
vested for detection of pAkt/Akt and nuclear p65/lamin
B1 proteins. We extracted the cytoplasmic and nuclear
protein fractions using NE-PER extraction reagents ac-
cording to the manufacturer’s protocol (Pierce Biotechnol-
ogy, IL, USA). Cytoplasmic and nuclear protein extracts
were used for Western blot analysis. The protein samples
(30 μg) were resolved on a 10% SDS-polyacrylamide gel
and transferred to polyvinylidenedifluoride membranes.
The membranes were then blocked with 5% skim milk in
Tween-20/ PBS and incubated with various primary anti-
bodies, including rabbit anti–phospho-Akt (Ser473), anti-
Akt (Cell Signaling Technology, Danvers, MA, USA),
anti-p65, and anti-lamin B1 (Santa Cruz, CA, USA) at 4°C
overnight. The blots were then incubated with horseradish
peroxidase–conjugated secondary antibodies at room
temperature for 60 min, and developed using the ECL™
Western Blotting System (Amersham Pharmacia Biotech,
Aylesbury, UK). The protein bands were quantified with
the FluorChem 8900 imaging system and the AlphaEa-
seFC software (Alpha Innotech Corp, CA, USA).
Superoxide measurement
Superoxide formation was measured using electron para-
magnetic resonance (EPR) spin trapping spectroscopy
[30]. Briefly, harvested lung, liver, and spleen tissues were
homogenized with 10 μg/mL chelex-treated PBS contain-
ing aprotinin, 0.5 μg/mL leupeptin, 0.7 μg/mL pepstatin,
and 500 μM PMSF. The protein samples (30 μg) were
mixed with 1 mM 1-hydroxy-3-carboxypyrrolidine (CPH)
and 0.1 mM diethyl-tetrapentaacetic acid (DTPA) to che-
late the ions of transition metals. The mixture was loaded
in 50-μL glass capillary tubes (Wilmad Glass, Buena, NJ,
USA). The electron paramagnetic resonance spectra were
recorded using an EMX Plus EPR spectrometer (Bruker
Biospin, Rheinstetten, Germany) equipped with an EMX-
m40X microwave bridge operating at 9.88 GHz.
Cytokine assays
The concentrations of IL-1β and IL-2 in the serum sam-
ples were determined using enzyme-linked immunosorb-
ent assay (ELISA) kits for IL-1β and IL-2 (lnvitrogen
Corporation, CA, USA), as per the manufacturer’s proto-
col. Sample concentrations were then calculated from a
standard curve. Results are expressed as picograms per
milligram (pg/mg) of protein.Statistical analysis
All results are presented as the mean ± standard error. An
overall analysis of the differences between the group
means was calculated by a one way analysis of variance
(ANOVA) and an appropriate post hoc test using SPSS
statistical software (SPSS 18, Chicago, IL, USA). A value of
P < 0.05 was considered to indicate statistical significance.
Results
Immediately after LPS injection, the mice showed pro-
nounced symptoms, including reduced mobility, ruffled
fur, hunched appearance, and lethargy. As shown in
Figure 1, after injection of 1000-μg LPS, 80% of the
C57BL/6 mice died within the first 24 h and 90% of the
mice died within 48 h. After injection of 500 μg LPS, no
mice died within the first 24 h; however, 90% of the mice
died within 48 h. No mortality was noted throughout
the experiment after injection of 100 μg of LPS. The
overall survival after 7 d in the mouse groups receiving
100-, 500-, and 1000-μg LPS injections was 100%, 10%,
and 10%, respectively (Figure 1A). In contrast, after in-
jection of 500 μg LPS in the Tlr4−/− mice, no mortality
was noted throughout the experiment. In addition, the
symptoms observed following LPS injection were less
pronounced during the entire observation period and
the mice regained full mobility quickly. When 1 mg/25 g
body weight LY294002 was injected 1 h prior to the ad-
ministration of LPS, 30% and 70% of the Tlr4−/− mice
died within 48 and 72 h, respectively (Figure 1B). The
overall 7-d survival of the Tlr4−/− mice following PI3K
inhibition and injection of 500 μg LPS was 30%. Injec-
tion with 1 mg/25 g body weight LY294002 alone did
not cause mortality in the Tlr4−/− mice.
Injection of 500 μg LPS in the C57BL/6 mice induced ac-
tivation of Akt at 3 and 6 h in the lung and liver (Figure 2);
however, injection of 500 μg LPS in the Tlr4−/− mice in-
duced more Akt phosphorylation after 3 and 6 h in the
lung and liver. There was no Akt phosphorylatoin being
detected in the spleen tissue of either C57BL/6 or Tlr4−/−
mice following LPS injection. Addition of LY294002 one
hour prior to LPS injection effectively blocked the activa-
tion of Akt in the lung and liver of the Tlr4−/− mice at 3
and 6 h post-treatment. In contrast, injection of 500 μg
LPS in the C57BL/6 mice induce the signficant NF-κB acti-
vation that presented as p65 nuclear translocation at 6 h in
the lung, at 3 h and 6 h in the liver, but not in the spleen
tissue. Addition of LY294002 one hour prior to LPS injec-
tion did not inhibit the p65 nuclear translocation in the
lung and liver of the C57BL/6 mice at 3 and 6 h post-
treatment. In the Tlr4−/− mice, LPS injection did not
induce significant p65 nuclear translocation in all three tis-
sues regardless of the presence or absence of LY294002
pretreatment. Injection of 500 μg LPS resulted in signifi-
cantly elevated EPR signals, which were indicative of
Figure 1 Survival study. (A) Survival rate of the C57BL/6 mice receiving intraperitoneal injections of 100, 500, or 1000 μg LPS from Escherichia
coli serotype 026:B6. Mice were monitored up to 7 days (n = 10 in each group) (B) Survival rate of the Tlr4−/− mice receiving intraperitoneal
injection of LY294002 (1 mg/25 g body weight) alone, 500 μg LPS alone, or 500 μg LPS with LY294002 injected 1 h prior.
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− levels, in the lung and liver of the C57BL/6
mice at 3 and 6 h post-treatment (Figure 3A). Addition of
LY294002 did not significantly change the elevated O2
−
levels in the lung and liver of the C57BL/6 mice at 3 and
6 h post-treatment. No change in the EPR signals was
noted in the spleen tissue after LPS injection at either 3 or
6 h. In contrast, no significant elevation in EPR signals was
found in the lung, liver, or spleen of Tlr4−/− mice receiving
injection of 500 μg LPS (Figure 3B). Inhibition of the PI3K
pathway with LY294002 one hour prior to LPS injection
significantly elevated the EPR signals in the lung and
liver tissue of the Tlr4−/− mice administered 500 μg LPS.
LY294002 pretreatment alone induced no remarkable
change in EPR signals in the spleen (Figure 3B).Figure 2 Akt phosphorylation and p65 nuclear translocatoin in the lu
6 h after intraperitoneal injection of 500 μg LPS in the absence or preAs shown in the Figure 4, 500-μg LPS injections in the
C57BL/6 mice significantly induced the expression of
IL-1β at 3 and 6 h as well as IL-2 at 3 h in the serum
post-treatment. LY294002 administration did not signifi-
cantly change the expression of IL-1β and IL-2 in the
serum of C57BL/6 mice 3 and 6 h after injection of
500 μg LPS. In contrast, injection of 500 μg LPS in the
Tlr4−/− mice resulted in a significantly lower induction
of IL-1β expression at 3 and 6 h as well as decreased IL-2
levels 3 h post-treatment, as compared to that in C57BL/6
mice. LY294002 administration significantly increased the
expression of IL-1β and IL-2 in the serum of Tlr4−/− mice
3 and 6 h after injection of 500 μg LPS. However, in the
Tlr4−/− mice, the increase in serum IL-1β following PI3Kng, liver, and spleen tissues of C57BL/6 and Tlr4−/− mice at 3 and
sence of LY294002 injected 1 h prior in quadruplicate.
Figure 3 Expression of superoxide. O2
− level detected by electron paramagnetic resonance (EPR) spin trapping spectroscopy in the lung, liver,
and spleen tissues of the (A) C57BL/6 or (B) Tlr4−/− mice at 3 and 6 h after intraperitoneal injection of 500 μg LPS in the absence or presence of
LY294002 injected 1 h prior. Bars represent mean ± SEM values from 6 experiments; *P < 0.05, **P < 0.01 vs. control.
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that in similarly treated C57BL/6 mice. The increase in
serum IL-2 levels in Tlr4−/− mice receiving LY294002 was
also not as high as that in C57BL/6 mice 3 h post-LPS
treatment. However, at 6 h post-treatment, the serum IL-2
levels in Tlr4−/− mice receiving LY294002 with LPS
stimulation were significantly higher than that in C57BL/6
mice under the same treatment conditions.
Discussion
In this study, we demonstrate that the innate resistance to
LPS toxicity in Tlr4−/− mice is reduced by inhibition of the
PI3K pathway, with a subsequent increase in mortalityand production of tissue superoxide and inflammatory cy-
tokines. There were many evidences that the the PI3K
pathway served as up- and down-stream relationship to
the TLR4 signaling pathway [4-9]. However, there were
some reports describing a parallel function of PI3K path-
way to balance the effect of TLR4 activation [18-20]. In
this study, LPS injection induced no NF-κB activation but
an increased Akt phosphorylation in the lung and liver of
the Tlr4−/− mice, when compared to that of the C57BL/6
mice, implying there is an important role of PI3K pathway
in mediating the inflammatory response in the TLR4-null
condition. These results also suggest that, following LPS
stimulation, there may be an alternative pathway for the
Figure 4 Cytokine expression. Levels of IL-1β and IL-2 in the serum of C57BL/6 or Tlr4−/− mice at 3 and 6 h after intraperitoneal injection of
500 μg LPS in the absence or presence of LY294002 injection 1 h prior. CTL: control. Bars represent mean ± SEM values of 6 experiments;
*P < 0.05, **P < 0.01 vs. control.
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MyD88 axis, and that this PI3K pathway upon activation
exerts anti-inflammatory effects under TLR4-null condi-
tions. Previously, it has also been demonstrated that inhib-
ition of PI3K activity increases LPS-induced interferon β
(IFN-β) synthesis [31,32]. In contrast, the LPS-induced
phosphorylation of Akt is markedly diminished in macro-
phages from IFN-β−/− mice [33]. However, relatively little
is known regarding the contribution of the MyD88-
independent pathway to PI3K activation.
TLR4 activates immune responses by sensing not only
microbial structures such as bacterial LPS but also some
endogenous “danger” molecules released by damaged host
cells [34,35]. Inflammatory responses induced by sterile
stimuli are very similar to responses during infection, and
are mediated by common receptors and pathways [36,37].
Multiple studies using TLR−/− animals or targeted gene si-
lencing of Tlr4 have shown that both inflammation and
injury responses like those in ischaemia/reperfusion (I/R)
are partially TLR4-dependent [14,38-40]. Similarly, there
is a balance between the TLR/NF-κB and PI3K/Akt signal-
ing pathways in mediating the inflammation and injury
response during sterile inflammation. For example, activa-
tion of the PI3K/Akt signaling pathway has been reported
to be associated with decreased myocardial ischemic in-
jury through the modulation of TLR4-mediated signaling
[41]. The ability of LPS pre-treatment to induce cardio-
protection following ischemia/reperfusion is mediated
through a PI3K/Akt-dependent mechanism [12]. Pharma-
cological inhibition of PI3K with LY294002 abrogated the
protective effect of LPS pre-treatment in myocardial I/R
injury [12].
In a study of time courses expression of inflammatory
mediators, including IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-9, IL-12(p40), IL-13, Eotaxin (CCL11), G-CSF,
GM-CSF, IFN-γ, KC (CXCL1), MCP-1 (CCL2), MIP-1α,(CCL3), MIP-1β (CCL4), RANTES (CCL5) and TNF-α,
of C57BL/6 mice receiving intraperitoneal injection of
LPS [42], significant inductions of all mediators were
found, with most mediators reached their maximum
around 6–12 h. Interesting, there was a rapid fall follow-
ing only 1 h rapid surge of TNFα. In addition, although
there was extraordinary high amounts of IL-6, which was
deemed as prototypical cytokine for endotoxemia and sep-
sis studies, around 3–12 h, there was no statistically sig-
nificant change at 24 h. In this study, we chosed IL-1β and
IL-2 as representive cytokines for measurement and re-
vealed that the administration of LY294002 prior to LPS
injection significantly increased the serum expression of
IL-1β and IL-2 in Tlr4−/− mice 3 and 6 h after injection of
500 μg LPS. These data are consistent with a report that
inhibition of PI3K in vivo resulted in significant increases
in circulating IL-1β, IL-2, IL-6, IL-10, IL-12, and TNF-α
during polymicrobial sepsis [20] as well as in vitro studies
[6] demonstrating the inhibitory effect of the PI3K/Akt
pathway on release of these cytokines. Notably, in the ab-
sence of LPS stimulation, inhibitors of Akt or PI3K had no
discernible effect on pro- or anti-inflammatory cytokine
production as compared to untreated controls [43]. Our
results demonstrated that, in the Tlr4−/− mice, the in-
crease in serum IL-1β and IL-2 levels 3 h after LPS treat-
ment and a concurrent inhibition of the PI3K pathway
was still not as high as the corresponding increase in
serum cytokine levels in C57BL/6 mice. In addition, at
6 h, the level of IL-2 in Tlr4−/− mice receiving LY294002
was significantly higher than that in the serum of the
C57BL/6 mice after LPS treatment. The significance and
mechanism of this differential regulation of in vivo cyto-
kine expression after PI3K inhibition in the Tlr4−/− mice is
not clear. However, it should also be noted that the precise
role of circulating cytokines in the pathophysiology of sep-
sis/septic shock is still controversial [44], and there is no
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cytokine levels and survival outcome in sepsis [44].
Conclusion
In this study, we demonstrate that innate resistance to
LPS toxicity in Tlr4−/− mice is impaired by inhibition of
the PI3K pathway, with a corresponding increase in
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